

NON-EXCLUSIVE PATENT LICENSE AGREEMENT

Between

Midwest Research Institute

And

[COMPANY NAME]

This License Agreement (hereinafter "Agreement"), which shall be effective on the date it is executed by the last Party to sign (the "Effective Date"), is between Midwest Research Institute (hereinafter "MRI"), Management and Operating Contractor for the National Renewable Energy Laboratory (hereinafter "NREL") located at 1617 Cole Blvd., Golden, Colorado 80401 and [COMPANY NAME], (hereinafter "Licensee"), a for-profit company organized and existing under the laws of the State of [NAME of STATE] and having a principal place of business at [COMPANY ADDRESS], hereinafter referred to individually as "Party" and jointly as "Parties".

BACKGROUND:

MRI manages and operates NREL under authority of its Prime Contract No. DE-AC36-99GO10337 (hereinafter "Prime Contract") with the United States Government as represented by the Department of Energy (hereinafter "DOE");

Inventions identified in Exhibit A (hereinafter "Inventions"), were conceived or first reduced to practice in the performance of work at NREL under the above Prime Contract. Pursuant to the terms of the Prime Contract and existing laws of the United States, MRI acquired rights in and to the Inventions;

Licensee is a [TYPE of BUSINESS] business located in [NAME of STATE], and as applicable, has worked closely with NREL on [DEFINE the TECHNICAL PARTNERSHIP TYPE], related projects;

Licensee plans to expand its current line of [TYPE] products by developing and commercializing a [PRODUCT LINE] based on the Inventions;

Licensee is interested in acquiring certain rights to MRI's Inventions. MRI is willing to grant such rights so that the Inventions will be developed and be used to the fullest extent possible for the benefit of the general public; and

As applicable, the Parties intend to or have entered into a Cooperative Research and Development Agreement related to this Agreement to develop commercial prototypes that embody the Inventions.

TERMS & CONDITIONS:

THEREFORE, in consideration of the foregoing premises, covenants and agreements contained herein, the Parties agree to be bound as follows:

1. Definitions.

1.1. “Licensed Inventions” means MRI’s United States and foreign patents and patent applications that are protected as NREL Protected Information under 35 U.S.C. §205. The Licensed Inventions are listed in Exhibit A, “Licensed Inventions” which, is hereby incorporated into this Agreement by reference. Any United States and foreign patents issuing from the patent applications listed in Exhibit A will be added to Exhibit A upon issuance. Licensed Inventions shall also include divisions, continuations (excluding continuations-in-part claiming new subject matter), reissues, substitutes, and extensions of the patents and patent applications as they arise.

1.2. “Licensed Products” means (a) any composition of matter, machine, article of manufacture, or component, or (b) processes, methods, or procedures, which if made used or sold by the Licensee or its sublicensees, would infringe one or more of the claims of the patents or patent applications covering the Licensed Inventions.

1.3. "Net Sales" means the gross selling price of Licensed Products as invoiced by Licensee and its sublicensees to purchasers for Licensed Products sold during a particular accounting period minus actual costs Licensee or its sublicensees incurred due to returns of Licensed Products, freight, and excise or other taxes (excluding income taxes) imposed on the production, sale, delivery, or use of the Licensed Products. When Licensed Products are used or transferred, but not sold by Licensee or its sublicensees, Net Sales shall mean the fair market value of the Licensed Products as if they were sold to an unrelated third party in similar quantities.

1.4. “Government” shall mean the United States of America.

1.5. “Improvements” means any improvements to the Licensed Inventions that (a) either directly or indirectly claim priority from the patents or patent applications of the Licensed Inventions and (b) are conceived or first reduced to practice during the term of this Agreement solely by MRI employees as a result of research and development activities for NREL and which if practiced without licensed rights would infringe one or more claims of the patent and patent applications covering the Licensed Inventions.

1.6. “Field of Use” means the field of use as defined in Exhibit B, “Fields of Use and Financial Considerations”.

2. Grants.

2.1. Subject to MRI’s rights in the Licensed Inventions and to the terms and conditions of this Agreement, including the terms as set forth in Exhibit B, “Fields of Use and Financial Considerations”, which is attached to this Agreement and hereby incorporated by reference, MRI hereby grants to Licensee the non-exclusive right and license, subject to certain Government rights set forth below in Section 2.2., and subject to the conditions set forth in Section 9.4, to

make, have made, use, or sell, the Licensed Inventions incorporated into the Licensed Products worldwide, subject to the patent coverage of the Licensed Inventions.

2.2. The right and license granted in Section 2.1 is subject to the following Government rights: (a) the Government has a paid-up, royalty-free, worldwide, nontransferable, irrevocable license to practice or have practiced by or on behalf of the Government the Licensed Inventions, and (b) the DOE's march-in rights as required by the Prime Contract and 35 U.S.C. § 203.

2.3. Licensee agrees that any Licensed Products for use or sale in the United States shall be substantially manufactured in the United States.

2.4. Licensee agrees to affix appropriate markings on the applicable Licensed Inventions upon or in association with the Licensed Products.

2.5. Sublicenses. [Applicable only if the Licensed Inventions are to be sublicensed, otherwise delete and RESERVE]

2.5.1. MRI hereby grants Licensee the right to grant sublicenses to make, use, and sell the Licensed Products, in the Fields of Use.

2.5.2. Sublicenses shall be subject to the requirements for substantial U.S. manufacture consistent with this Agreement.

2.5.3. MRI shall have the right to deny approval of any sublicense granted hereunder if it chooses to do so, including the terms and conditions of the sublicense. The Licensee shall not sublicense any rights that are not consistent with the terms, scope, and Field of Use of this Agreement.

2.5.4. Licensee shall provide MRI with a signed copy of each sublicense it executes within fourteen (14) days after the sublicense is executed.

2.5.5. The royalty paid to MRI for consideration of whatever kind Licensee receives from sublicenses shall not be less than the royalty rate Licensee is obligated to pay in Exhibit B of this Agreement.

2.5.6. If this Agreement is terminated for any reason, except breach of contract by MRI, Licensee shall immediately assign all of its right, title, and interest in all sublicenses to MRI, including the right to receive income and shall provide MRI and its sublicensees with written notice of the assignment.

2.5.7. To the extent that Licensed Inventions include any information marked "NREL Protected Information" pursuant to this Agreement; Licensee will be required to ensure that upon termination of sublicenses, Licensee will recover all such information from its sublicensees and return NREL Protected Information to MRI.

2.5.8. Licensee will include the following Sections in its sublicenses for the making, using, and selling of the Licensed Products incorporating the Licensed Inventions: 2.3., 2.4., 2.5., 6.4, 6.6, 6.7, 7.1., 7.2., 7.3., 9., 13., 14., 18 and 19.

2.6. MRI hereby grants Licensee a thirty (30) day right of first refusal to enter into negotiations with MRI to incorporate Improvements into this Agreement by amendment provided that: (a) MRI obtains title to such Improvements; (b) there are no pre-existing legal constraints or obligations that would prevent MRI from licensing Improvements to Licensee; and (c) Improvements are applicable within the Field of Use. If MRI and Licensee agree to incorporate such Improvements into this Agreement, the Improvements will be added to the list of Licensed Inventions included in Exhibit A and other negotiated terms that serve to amend this Agreement will be added or deleted as appropriate. [Applicable if licensee has an option to license Improvements, otherwise delete and RESERVE]

3. Financial Obligations and Commercialization Plan.

3.1. In consideration of the rights and license granted herein, Licensee agrees to the provisions of Exhibit B, “Fields of Use and Financial Considerations” and Exhibit C, “Development and Commercialization Plan”, attached to this Agreement and hereby incorporated by reference.

3.2. Licensee and its sublicensees shall owe no royalties to MRI on any acquisitions involving Government funds if such sales reflect a discount that is greater than or equal to the amount Licensee would owe to MRI under this license, because of the Government’s retained license in the Licensed Inventions.

3.3. Licensee shall report the Net Sales price paid by the purchaser for acquisitions or use of the Licensed Products involving Government funds under the Records, Reports, and Royalty Payments Section of this Agreement. This report will also include (a) a Government control number (if available); and (b) identification of the Government agency for each sale.

3.4. Upon termination of this Agreement for any reason whatsoever, Licensee shall report and pay to MRI, within thirty (30) days of such termination, any financial obligations including, but not limited to, fees, payments, royalties, reimbursements, interest, and other forms of consideration, due and owing MRI.

4. Records, Reports, and Royalty Payments.

4.1. Licensee agrees to: (a) keep adequate and sufficiently detailed records to enable Licensee’s financial obligations as required under this Agreement to be readily determined; and (b) within forty-eight (48) hours provide such records for inspection and copying by MRI’s authorized representatives, with reasonable notice, at any time during Licensee’s regular business hours.

4.1.1. Licensee agrees that it shall also provide MRI with any additional records that MRI reasonably determines are necessary to verify any records that Licensee is required to generate or maintain to fulfill the requirements listed in Exhibits B and C.

4.1.2. Licensee agrees to make any records that it is required to generate or maintain under the terms of this Agreement available for inspection by MRI’s authorized representatives for three (3) years after the last royalty period to which the records refer.

4.2. Licensee shall provide MRI with a written report certified by an officer of Licensee that complies with the requirements of the Notices and Payments Section and Section 3.3 of this Agreement no later than thirty (30) days after the end of each calendar year for the life of this Agreement that identifies the following information for the immediately preceding calendar year: (a) all Net Sales of the Licensed Products made by Licensee in U.S. Dollars itemized by domestic and/or foreign rights that are subject to this Agreement including acquisitions involving Government funds and all export Net Sales, and if none to so indicate; (b) all Net Sales in U.S. Dollars made by sublicensees, itemized by domestic and/or foreign rights that are subject to this Agreement including acquisitions involving Government funds and all export Net Sales, and if none to so indicate; and (c) amount of each payment due MRI for patent costs reimbursement, upfront fees, minimum annual royalties and continuous royalties based on Net Sales of Licensed Products. Accompanying the annual written report will be the full payment due in U.S. Dollars, for the preceding calendar year, pursuant to the terms of this Agreement.

4.3. Licensee shall make financial payments to the order of MRI in U.S. dollars in accordance with Exhibit B and Section 4.2 above.

4.4. If Licensee fails to make any payment to MRI that may be required under this Agreement within the time period prescribed for such payment, then the unpaid amount shall bear interest at the rate of one and one half percent (1.5%) per month, or other authorized statutory rate, if higher, from the date when the payment was due until payment in full, with interest, is made. Should Licensee have need to delay a payment when due, MRI will consider Licensee's needs as presented, in writing to MRI at the address set forth in Section 12.1, by Licensee and received by MRI thirty (30) days before the required reporting and payment date. Under such conditions, MRI may, at its sole discretion, extend the date upon which an annual payment is required.

5. Infringement by Third Parties.

5.1. Licensee and MRI shall promptly give notice in writing to each other of any known actual or potential infringement of the Licensed Inventions. In the event any patent applications and patents of the Licensed Inventions are infringed by an unlicensed third party, Licensee and MRI shall have the right to abate or prevent such infringement as follows.

5.1.1. MRI shall have the primary right, but not the obligation, to take appropriate action in connection with any proceeding or suit to abate or to prevent an infringement. Before commencing any action to abate or to prevent the infringement, MRI will first consult with the DOE, as required by the Litigation and Claims provision of the Prime Contract between DOE and MRI, and in the event DOE authorizes MRI to undertake an infringement suit, MRI shall further consult with Licensee to determine if Licensee also wishes to enter into such suit. Licensee shall have the right to be represented by counsel at the suit proceedings and to participate therein at its own cost, but shall not have the right to control the suit. Licensee agrees to cooperate with, and give reasonable assistance to, MRI in abating or preventing an infringement.

5.1.2. The cost and expenses of all suits brought by MRI under Section 5.1.1 above shall be equally shared by both Parties out of any settlement amount, damages or other monetary awards recovered in favor of MRI and/or Licensee. MRI shall be entitled to

receive and retain for its own use and benefit any settlement amount or remaining damages awarded in such suit. In the event Licensee refuses to cooperate and give reasonable assistance to MRI, then all settlements, damages and awards shall belong to MRI.

5.1.3. Under Section 5.1.1 above, if MRI does not take appropriate action to abate or prevent an infringement within one hundred twenty (120) days after receiving notice, Licensee is empowered, or has the right, with the written authorization of MRI which will not be unreasonably denied, to file suit in its own name by counsel of its choice to the extent provided by applicable laws, rules and regulations, provided no settlement or consent judgment or other voluntary final disposition of the infringement suit is entered into without the approval of MRI which will not be unreasonably withheld.

5.1.4. In MRI authorized infringement suits brought solely by Licensee pursuant to Section 5.1.3 above, Licensee shall not be acting as the agent, or in any way on behalf of, MRI. In such suits, MRI, with the consent of the Contracting Officer, shall provide reasonable assistance to Licensee to abate or prevent the infringement.

5.2. In MRI authorized infringement suits brought solely by Licensee pursuant to 5.1.3 above, all costs and expenses associated therewith shall be the responsibility of Licensee alone, and in such an event, all settlements, damages or other monetary awards shall belong to Licensee alone.

5.3. MRI and DOE shall have the right to be represented by counsel of its choice in any infringement proceeding or suit taken by Licensee pursuant to Section 5.1.3 above.

5.4. MRI and the Government shall not be liable for any costs or losses incurred as a result of an action for infringement brought against the Licensee and/or its sublicensees as a result of Licensee's exercise of any right granted under this Section 5, and Licensee shall indemnify and hold MRI, the Government, their officers, employees and agents harmless against all liability, expenses and costs, including attorneys' fees incurred as a result of any such suit.

6. Representations and Warranties.

6.1. MRI represents and warrants that MRI can grant the rights, licenses, and privileges granted by this Agreement.

6.2. MRI represents and warrants that MRI has no actual knowledge of any infringement claims filed against MRI for practicing the Licensed Inventions anywhere in the world.

6.3. Except as set forth in this Section 6, MRI makes **NO REPRESENTATIONS OR WARRANTIES**, express or implied, with regard to infringement of any Licensed Inventions.

6.4. Licensee represents and warrants that it shall not export any technical information (or the direct product thereof) furnished to Licensee, either directly or indirectly by MRI in the grant of a license to the Licensed Inventions, from the United States of America, directly or indirectly without first complying with all requirements of the Export Administration Regulations, including the requirement for obtaining any export license, as applicable.

6.5. Licensee warrants that it will not grant any rights inconsistent with the terms, scope and Fields of Use of this Agreement and that copies of all negotiated and executed sublicenses shall be provided to MRI in accordance with Section 2.5.4.

6.6. Licensee agrees to indemnify, defend and hold harmless MRI, DOE and the Government, its officers, agents and employees from all liability involving the violation of such export regulations, either directly or indirectly, by Licensee or its sublicensees.

6.7. Licensee acknowledges it may be subject to criminal liability under U.S. laws for Licensee's failure to obtain any required export licenses.

7. Limitations of Warranties, Indemnification and Insurance.

7.1 Neither NREL, MRI, the DOE, the Government nor persons acting on their behalf will be responsible for any injury to or death of persons, or damage to or destruction of any property, or for any other loss, damage, or injury of any kind whatsoever resulting from Licensee's manufacture, use, or sale of the Licensed Inventions, or Licensed Products, in whatever form furnished hereunder, absent any negligent act or omission on the part of NREL, MRI, DOE and/or the Government.

7.2. THE PARTIES AGREE THAT NEITHER NREL, MRI, DOE, THE GOVERNMENT, NOR PERSONS ACTING ON THEIR BEHALF MAKE ANY WARRANTY, EXPRESS OR IMPLIED:

7.2.1. WITH RESPECT TO THE MERCHANTABILITY, ACCURACY, COMPLETENESS, OR USEFULNESS OF ANY LICENSED INVENTIONS, PATENT APPLICATIONS, ISSUED PATENTS, LICENSED PRODUCTS, OR NREL PROTECTED INFORMATION FURNISHED HEREUNDER;

7.2.2. THAT THE USE OF ANY LICENSED INVENTIONS, PATENT APPLICATIONS, ISSUED PATENTS, LICENSED PRODUCTS, OR NREL PROTECTED INFORMATION MAY NOT INFRINGE ANY PRIVATELY OWNED RIGHTS;

7.2.3. THAT ANY LICENSED INVENTIONS, PATENT APPLICATIONS, ISSUED PATENTS, LICENSED PRODUCTS, OR NREL PROTECTED INFORMATION FURNISHED HEREUNDER WILL NOT RESULT IN INJURY OR DAMAGE WHEN USED FOR ANY PURPOSE; OR

7.2.4. THAT ANY LICENSED INVENTIONS, PATENT APPLICATIONS, ISSUED PATENTS, LICENSED PRODUCTS, OR NREL PROTECTED INFORMATION FURNISHED HEREUNDER WILL ACCOMPLISH THE INTENDED RESULT OR ARE SAFE OR FIT FOR ANY PURPOSE, INCLUDING THE INTENDED OR PARTICULAR PURPOSE;

7.2.5. NREL, DOE, MRI AND THE GOVERNMENT HEREBY SPECIFICALLY DISCLAIM ANY AND ALL WARRANTIES, EXPRESS OR IMPLIED, FOR ANY LICENSED INVENTIONS, PATENT APPLICATIONS, ISSUED PATENTS,

NREL PROTECTED INFORMATION, OR LICENSED PRODUCTS MANUFACTURED, USED, OR SOLD BY LICENSEE.

7.2.6. NEITHER NREL, DOE, MRI NOR THE GOVERNMENT SHALL BE LIABLE FOR LOST PROFITS, LOST SAVINGS, SPECIAL, CONSEQUENTIAL, INCIDENTAL OR OTHER INDIRECT DAMAGES IN ANY EVENT, EVEN IF SUCH PARTY IS MADE AWARE OF THE POSSIBILITY THEREOF.

7.3. Except for any liability resulting from any negligent act or omission of NREL, the DOE, the Government or MRI, Licensee shall indemnify and hold harmless NREL, the DOE, the Government and MRI, and their officers, employees, and agents, for all damages, costs, and expenses, including attorneys' fees, arising from death, personal injury or property damage to third parties occurring as a result of the commercialization and utilization of the Licensed Inventions by Licensee and its sublicensees, if any, including but not limited to, the making, using, selling, or exporting of products, processes, or services by or on behalf of the Licensee, its assigns, or licensees which was derived from the work or activities performed under this Agreement. This indemnification shall include, but not be limited to, indemnification for any product liability resulting from the commercialization and utilization of the Licensed Inventions by Licensee and its sublicensees, if any. The indemnity set forth in this Section 7.3. shall apply only if Licensee shall have been informed as soon as practical by NREL, MRI and/or the DOE or the Government of the action alleging such claim and shall have been given an opportunity, to the extent afforded by applicable laws, rules, or regulations, to participate in and control its defense, and the NREL, MRI and/or the DOE or the Government shall have provided reasonably available information and reasonable assistance (at Licensee's cost) as requested by Licensee. No settlement for which Licensee shall be responsible shall be made without Licensee's consent unless required by final decree of a court of competent jurisdiction.

7.4 Beginning at the time when any Licensed Products are being distributed or sold (including for the purpose of obtaining regulatory approvals) Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than \$8,000,000 per incident and \$20,000,000 annual aggregate, and Licensee shall have the DOE, the Government, NREL and MRI, its officers, employees and agents named as additional insureds. Such commercial general liability insurance shall provide (i) product liability coverage; (ii) broad form contractual liability coverage for Licensee's indemnification under this Agreement; and (iii) coverage for litigation costs. The minimum amounts of insurance coverage required shall not be construed to create a limit of Licensee's liability with respect to its indemnification obligations under this Agreement.

7.5 Licensee shall provide MRI with written evidence of such insurance upon MRI's written request. Licensee shall provide MRI with written notice of at least fifteen (15) days before a material change in such insurance.

7.6 Licensee shall maintain such commercial general liability insurance beyond the expiration or termination of this Agreement during (a) the period that any Licensed Products are practiced or processes covered by this Agreement are being commercially distributed or sold by Licensee or by a sublicensee, if any, or agent of Licensee; and (b) the five (5) year period immediately after such period described in subsection (a).

8. Reimbursement of Patent Costs and Technical Assistance.

8.1 Licensee will reimburse MRI for all patent prosecution and maintenance costs (“Costs”) for all Licensed Inventions as listed in Exhibit A accruing on and after the Effective Date of this Agreement. In the case where Licensed Inventions are licensed to other licensees, Licensee will reimburse MRI for actual Costs on a pro rata basis with MRI and other licensees for said non-exclusively licensed inventions. Invoices for such costs will not exceed actual costs and are due and payable no later than thirty (30) days after receipt of invoices by Licensee.

8.2 MRI agrees, upon the written request of Licensee, to assist Licensee in obtaining technical assistance from NREL subject to the availability of the required resources and under the appropriate agreements. The Licensee shall pay full cost in accordance with the Prime Contract with the Government for the cost of such technical assistance.

9. Term of Agreement and Early Termination.

9.1. Subject to early termination as set forth in this Section and the terms and conditions set forth in Exhibits B and C, this Agreement shall be effective for as long as the Licensed Inventions are enforceable.

9.2. Either Party shall have the right to terminate this Agreement with cause and without judicial resolution upon written notice to the other after the non-breaching Party notifies the asserted breaching Party of a breach of any provision of this Agreement and the asserted breach has not been cured by the asserted breaching Party within sixty (60) calendar days from receipt of such notice (“Cure Period”). If at the end of the Cure Period the asserted breach has not been cured and there remains a dispute or controversy, the Parties may agree to seek to resolve the matter through the use of the procedures set forth in Section 19.1 below. If MRI is the non-breaching Party under this Section 9.2, then Licensee shall, within thirty (30) calendar days, owe MRI all then appropriate patent cost reimbursements, if applicable, a) upfront fees; and b) continuous royalties due or the pro rata portion of any minimum annual royalties due at the end of the calendar year of such termination, whichever is greater. Licensee acknowledges and agrees that MRI shall be entitled to seek any additional remedies available at law to MRI for Licensee’s breach of this Agreement.

9.3. This Agreement shall terminate automatically upon a final adjudication of invalidity, unenforceability, or the extinguishment of all Licensed Inventions, for any reason.

9.4. If Licensee fails to satisfy the requirements of Exhibits B and C then MRI shall have the right, to exercise at its sole discretion with thirty (30) days written notice to Licensee, to terminate this Agreement in accordance with its early termination requirements.

9.5. Subject to sublicenses granted, if any, and consistent with the requirements of this Agreement, the Parties agree that MRI, at its sole discretion, may immediately terminate this Agreement upon any attempted transfer of Licensee's interest in this Agreement, in whole or in part, to any other party except to a wholly owned subsidiary of the Licensee or as may be otherwise permitted by the terms of this Agreement.

9.6. Licensee agrees that this Agreement shall automatically terminate if Licensee attempts, in any way, to pledge its rights under this Agreement as collateral to a third party.

9.7. Licensee hereby agrees that in the event Licensee by its own actions or the action of any of its shareholders or creditors (if applicable), files or has filed against it, with an order for relief being entered, a case under the Bankruptcy Code of 1978, as previously or hereafter amended, MRI shall be entitled to relief from the automatic stay of Section 362 of Title 11 of the U.S. Code, as amended, on or against the exercise of the rights and remedies available to MRI; and Licensee hereby waives the benefits of such automatic stay and consents and agrees to raise no objection to such relief. Licensee further agrees that MRI, at its sole discretion, may immediately terminate this Agreement by means of a written notice to Licensee in the event that a creditor or other claimant takes possession of, or a receiver, administrator or similar officer is appointed over any of the assets of Licensee, or in the event that Licensee makes any voluntary arrangement with its creditors or becomes subject to any court or administration order pursuant to any U.S. Bankruptcy proceeding or insolvency law. Licensee will promptly inform MRI of its intention to file a voluntary petition in bankruptcy or of another's communicated intention to file an involuntary petition in bankruptcy.

9.8. Licensee may terminate this Agreement without cause if Licensee provides MRI with sixty (60) days prior notice and pays MRI: (a) all patent cost reimbursement, as applicable, and all upfront fees due at the time of termination; and (b) the greater of: the sum of the accrued continuous royalties due or the sum of the pro rata portion of any minimum annual royalties due at the end of the accounting period of such termination and the minimum annual royalty due for the accounting period immediately following termination.

10. Rights of Parties after Termination.

10.1. Neither Party shall be relieved of any obligation or liability under this Agreement arising from any act or omission committed prior to the termination date.

10.2. From and after any termination of this Agreement, Licensee and its sublicensees, if any shall have the right to sell only those Licensed Products in Licensee's inventory at the time of termination, provided that Licensee has satisfied all financial obligations and reporting requirements required by this Agreement. Except as otherwise provided in this Section, Licensee shall not exercise any of the rights granted under this Agreement after it is terminated.

10.3. The rights and remedies granted herein, and any other rights or remedies which the Parties may have, either at law or in equity, are cumulative and not exclusive of others. On any termination, Licensee shall duly account to MRI and transfer to it all rights to which MRI may be entitled under this Agreement.

10.4. The following Sections are intended to survive the termination of this Agreement: 2.5 (if applicable), 3, 4, 6, 7, 8.1, 9, 10, 14, 15, 16, 18, and 19.

11. Force Majeure.

No failure or omission by MRI or by Licensee in the performance of any obligation under this Agreement shall be deemed a breach of this Agreement or create any liability if the same shall arise from acts of God, acts or omissions of any government or agency thereof, compliance with rules, regulations, or orders of any governmental authority or any office, department, agency, or instrumentality thereof, fire, storm, flood, earthquake, accident, acts of the public enemy or terrorism, war, rebellion, insurrection, riot, sabotage, invasion, quarantine, restriction, transportation embargoes, or failures or delays in transportation. The circumstances surrounding such failure or omission shall be communicated to the affected Party in writing within fifteen (15) business days of such event.

12. Notices and Payments.

12.1. All notices and reports shall be addressed to the Parties as follows:

If to MRI:

National Renewable Energy Laboratory
Attn: Office of Technology Transfer
1617 Cole Blvd., MS 1635
Golden, CO 80401

Facsimile No.
(303)275-3040
Telephone No.
(303) 275-4269
E-mail Contact
viktoriva_esayev@nrel.gov

If to Licensee:

Attn: _____

Facsimile No.

Telephone No.

E-Mail Contact

12.2. All financial obligations due to MRI shall be sent to:

National Renewable Energy Laboratory
Attn: Royalty Cashier
1617 Cole Blvd., MS 1723A
Golden, CO 80401

A copy of all financial obligations shall be sent to NREL’s Office of Technology Transfer at the above address in Section 12.1.

12.3. Any notice, report or any other communication required or permitted to be given by one Party to the other Party by this Agreement shall be in writing and either: (a) served personally on the other Party; (b) sent by express, registered or certified first-class mail, postage prepaid, addressed to the other Party at its address as indicated above, or to such other address as the addressee shall have previously furnished to the other Party by proper notice; (c) delivered by commercial courier to the other Party; or (d) sent by facsimile to the other Party at its facsimile number indicated above or to such other facsimile number as the Party shall have previously furnished to the other Party by proper notice, with machine confirmation of transmission.

13. Non-Abatement of Royalties.

MRI and Licensee acknowledge that certain of the Licensed Inventions may expire prior to the conclusion of the term of this Agreement. However, MRI and Licensee agree that the royalty rates provided for in Exhibit B shall be uniform and undiminished for as long as any claim of, or other intellectual property right in, any of the Licensed Inventions are enforceable except as otherwise provided in this Agreement.

14. Confidential Information.

14.1. The Parties agree that all information, marked by Licensee as “Proprietary” or MRI as “NREL Protected Information” and forwarded to one by the other for the purposes of this Agreement (a) are to be received in strict confidence, (b) are to be used only for the purposes of this Agreement, and (c) are not to be disclosed by the recipient Party, its agents or employees without the prior written consent of the other Party, except to the extent that the recipient Party can establish by competent written proof that such information:

14.1.1 was in the public domain at the time of disclosure;

14.1.2 later became part of the public domain through: (A) no act or omission of the recipient, its employees, agents, successors or assigns and (B) no breach by a third party with an obligation of confidentiality to the disclosing party;

14.1.3 was lawfully disclosed to the DOE or recipient Party by a third party having the right to disclose it;

14.1.4 was already known by the DOE or recipient Party at the time of disclosure which can be shown by competent evidence;

14.1.5 was independently developed by the DOE or recipient Party without the utilization of the other party’s protected property and information; or

14.1.6. is required by law or regulation to be disclosed, provided however, that the disclosing Party shall first give the recipient written notice and adequate opportunity to object to such order for disclosure or to request confidential treatment.

15. Waivers.

15.1. The failure of MRI at any time to enforce any provisions of this Agreement or to exercise any right or remedy shall not be construed to be a waiver of such provisions or of such rights or remedy or the right of MRI thereafter to enforce each and every provision, right or remedy.

15.2. The waiver of a specific breach hereunder may be effectuated only by a written document, signed by the waiving Party, and delivered to the breaching Party. Such formal waiver shall not constitute a waiver of any other breach.

16. Entire Agreement and Legal Amendments.

16.1. The Parties expressly understand and agree that this instrument contains the entire agreement between the Parties with respect to the subject matter of this Agreement and that all prior representations, warranties, or agreements relating to this subject matter have been merged into this instrument and are thus superseded in totality by this Agreement. This Agreement may be amended only by a written instrument signed by the duly authorized representatives of both of the Parties.

16.2. The Parties agree that if any part, term, or provision of this Agreement shall be found illegal or in conflict with any valid controlling law, the validity of the remaining provisions shall not be affected thereby.

16.3. In the event the legality of any provision of this Agreement is brought into question because of a decision by a court of competent jurisdiction of any country in which this Agreement applies, MRI, by written notice to Licensee, may revise the provision in question or may delete it entirely so as to comply with the decision of said court.

17. Headings.

The headings for the Sections set forth in this Agreement are strictly for the convenience of the Parties hereto and shall not be used in any way to restrict the meaning or interpretation of the substantive language of this Agreement.

18. Successor Contractor.

Licensee acknowledges and agrees that MRI may transfer this Agreement and all rights, duties and obligations hereunder, to the DOE or a successor management and operating contractor of NREL as may be required under the Prime Contract with DOE.

19. Disputes and Governing Laws.

19.1. This Agreement, and the rights and liabilities of the parties with respect to this Agreement and its subject matter, shall be governed by the laws of the State of Colorado, without reference to the principles of conflicts of laws thereof. Any dispute arising out of or relating to this Agreement or its subject matter not settled by the parties may be resolved only by the courts of the State of Colorado, or if subject matter jurisdiction exists, by the United States federal courts, with venue in the County of Denver (in the case of state court) or in the U.S. District Court for the District of Colorado (in the case of federal court). Each of the parties hereby consents to the jurisdiction of such courts over it in any action involving any such dispute. Each of the parties agree not to commence or maintain a legal proceeding involving any such dispute in any forum except a court of the State of Colorado located in Denver County or the United States District Court for the District of Colorado (other than to enforce a judgment obtained in such courts) and agrees not to contest the venue of any action involving any such dispute in the County of Denver or the District of Colorado, as the case may be, nor to assert in any such court the doctrine of forum non conveniens, or the like.

19.2. If any provisions of this Agreement are held to be invalid, illegal, or unenforceable in any respect, that invalidity, illegality, or unenforceability will not affect any other provisions of this Agreement. This Agreement will be construed as if the invalid, illegal, or unenforceable revision were never in this Agreement.

19.3. MRI will release information concerning this Agreement if required by law. In publicizing anything made, used, offered for sale, sold or imported under this Agreement, Licensee, and all sublicensees, if any, shall not use the name of MRI, NREL or DOE or otherwise refer to any organization related to MRI or DOE, except with the prior written approval of MRI and DOE.

20. Counterparts.

This Agreement may be executed in separate counterparts, each of which so executed and delivered shall constitute an original, but all such counterparts shall together constitute one and the same instrument. Any such counterpart may comprise one or more duplicates or duplicate signature pages, any of which may be executed by less than all of the Parties, provided that each Party executes at least one such duplicate or duplicate signature page. The Parties stipulate that a photo static copy of an executed original will be admissible in evidence for all purposes in any proceeding as between the Parties.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed in their respective names by their duly authorized representatives.

For **MRI**

By: _____

Name: (typed) _____

Title: Director of the Office of Technology Transfer _____

Date: _____

For **Licensee**

By: _____

Name: (typed) _____

Title: _____

Date: _____

EXHIBIT A: LICENSED INVENTIONS

NREL ROI No.	Country	Title	Patent/Patent Application No.	Filing/Issue Date

Initials

MRI: _____ Licensee: _____

Date: _____ Date: _____

EXHIBIT B: FIELDS OF USE AND FINANCIAL CONSIDERATIONS

- A. **Fields of Use:** Using the Licensed Inventions to make, use, and sell the Licensed Products for [**PRODUCT LINE**] in the following applications:

Primary application:

Secondary application:

- B. **Upfront Fee:**

- C. **Continuous Royalty Rate Structure:**

Table 1: Continuous Royalty Rates for Net Sales of Licensed Products

Accounting Period	Continuous Royalty	Due Date

- D. **Minimum Annual Royalty Payments:**

In addition to the continuous royalties paid to MRI for the sale of Licensed Products under Table 1, Licensee shall pay MRI a minimum annual royalty regardless of actual manufacture, use or sale of any Licensed Products on the due dates and in the manner shown in Table 2 herein below. MRI shall have the remedy set forth at Section 9.4 of this Agreement upon the failure by the Licensee in any one year to timely pay the minimum annual royalty called for in Table 2.

If in any given year, the continuous royalty reported and paid by Licensee to MRI pursuant to Table 1 exceeds the minimum annual royalty called for in Table 2 for such given year, Licensee shall pay to MRI the total amount of the minimum annual royalty required for that given year, and pay to MRI in continuous royalties the difference between said required minimum annual royalty and the total amount of continuous royalties payable to MRI for said given year.

Table 2: Minimum Annual Royalties

Calendar Year	Min. Royalties (USD)	Due Date

- E. **Sublicensing Royalties:**

As appropriate, sublicensing royalty payments due MRI from Licensee for Net Sales by sublicensees will be at the same rate and schedule as set forth in Section C above. Licensee will be responsible for overseeing, collecting, reporting, and submitting royalties from sublicensees to MRI.

NOTICE

This Exhibit contains financial and commercial information that is BUSINESS SENSITIVE and the Parties hereby agree not to use or disclose this Exhibit to any third party without the advance written approval of the other Party, except: (1) to those necessary to enable the Parties to perform under this Agreement; (2) as may be required by the MRI Prime Contract with the DOE under the same restrictions as set forth herein; or (3) in event of breach of any provision of this Agreement by either Party, to those deemed necessary by the non-breaching Party to enforce the non-breaching Party's rights under the Agreement.

Initials

MRI: _____

Licensee: _____

Date: _____

Date: _____

EXHIBIT C: DEVELOPMENT AND COMMERCIALIZATION PLAN

Licensee represents and warrants that it will invest in the development of the technology and market for Licensed Products by committing Licensee’s resources, at a minimum, to the following requirements:

- 1) **Technical Milestones:**

- 2) **Market Milestones:**

Progress and substantiation of Licensee meeting these development and commercialization requirements shall be provided to MRI in the form of a report to be presented in writing at a meeting between the Parties to be held at the mutual convenience of said Parties but no later than sixty (60) days from the Effective Date and each anniversary thereafter of the Effective Date thereof.

NOTICE

This Exhibit contains financial and commercial information that is BUSINESS SENSITIVE and the Parties hereby agree not to use or disclose this Exhibit to any third party without the advance written approval of the other Party, except: (1) to those necessary to enable the Parties to perform under this Agreement; (2) as may be required by the MRI Prime Contract with the DOE under the same restrictions as set forth herein; or (3) in event of breach of any provision of this Agreement by either Party, to those deemed necessary by the non-breaching Party to enforce the non-breaching Party’s rights under the Agreement.

Initials

MRI: _____ Licensee: _____

Date: _____ Date: _____